Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Medis Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (1457)
ARTG (51)
Cancellation or suspension (26)
Listed medicine compliance report (5)
Prescription medicine registration (2)

Date

2025 (58)
2024 (1215)
2023 (3)
2022 (29)
2021 (106)
2020 (31)
2019 (6)
2018 (3)
2017 (44)
2016 (5)
2015 (17)
2014 (7)
2013 (2)
2012 (7)
2011 (6)
2010 (1)
2009 (1)

Search

Sponsor content

1541 result(s) found, displaying 231 to 240

ROCAN 0.2% (w/v) ropivacaine hydrochloride (as monohydrate) 40 mg/20 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

17 September 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ROCAN 0.2% (w/v) ropivacaine hydrochloride (as monohydrate) 200 mg/100 mL solution for injection bag Cancelled under Section 30(1)(c) of the Act

17 September 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ROCAN 0.2% (w/v) ropivacaine hydrochloride (as monohydrate) 20 mg/10 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

17 September 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ROCAN 0.75% (w/v) ropivacaine hydrochloride (as monohydrate) 75 mg/10 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

17 September 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ROCAN 0.75% (w/v) ropivacaine hydrochloride (as monohydrate) 150 mg/20 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

17 September 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
RISPERIDONE ASCENT risperidone 2mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

17 September 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
RISPERIDONE ASCENT risperidone 1mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

17 September 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
RISPERIDONE ASCENT risperidone 0.5mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

17 September 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ESCITALOPRAM ACTAVIS escitalopram (as oxalate) 5 mg tablet blister Cancelled under Section 30(1)(c) of the Act

17 September 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ESCITALOPRAM ACTAVIS escitalopram (as oxalate) 20 mg tablet blister Cancelled under Section 30(1)(c) of the Act

17 September 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd

Pages

First page
Previous page
…
Page 20
Page 21
Page 22
Page 23
Current page 24
Page 25
Page 26
Page 27
Page 28
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.